Literature DB >> 9347078

Hormonal (ACTH, cortisol, beta-endorphin, and met-enkephalin) and cardiovascular responses to hyperthermic stress in chronic alcoholics.

P P Vescovi1, C DiGennaro, V Coiro.   

Abstract

Chronic alcohol drinking causes profound alterations in hypothalamic-pituitary function. In the present study, endocrine [corticotropin (ACTH), beta-endorphin, cortisol, and met-enkephalin] and cardiovascular (blood pressure) changes in response to hyperthermic stress (sauna at 90 degrees C for 30 min) were evaluated in 25 normal men (25 to 50 years old) and in 48 male alcoholic subjects (34 to 56 years old) after 5 weeks of abstinence. Significantly lower increments in systolic blood pressure were observed in alcoholics than in control subjects. Furthermore, alcoholics showed lower ACTH, beta-endorphin, and cortisol increments in response to sauna than normal controls. In contrast, sauna-induced hyperthermia did not change significantly the circulating met-enkephalin levels in either normal controls or chronic alcoholics. These data suggest that an impairment in the adaptive response to stress affects alcoholic men even after a few weeks of abstinence from alcohol.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9347078

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  10 in total

1.  Adrenocortical and pituitary glucocorticoid feedback in abstinent alcohol-dependent women.

Authors:  Bryon Adinoff; Susan E Best; Wen Ye; Mark J Williams; Ali Iranmenesh
Journal:  Alcohol Clin Exp Res       Date:  2010-03-10       Impact factor: 3.455

2.  Suppression of the HPA axis stress-response: implications for relapse.

Authors:  Byron Adinoff; Klaus Junghanns; Falk Kiefer; Suchitra Krishnan-Sarin
Journal:  Alcohol Clin Exp Res       Date:  2005-07       Impact factor: 3.455

3.  Social defeat increases alcohol preference of C57BL/10 strain mice; effect prevented by a CCKB antagonist.

Authors:  A P Croft; S P Brooks; J Cole; H J Little
Journal:  Psychopharmacology (Berl)       Date:  2005-11-09       Impact factor: 4.530

Review 4.  Oxytocin for the treatment of drug and alcohol use disorders.

Authors:  Mary R Lee; Elise M Weerts
Journal:  Behav Pharmacol       Date:  2016-12       Impact factor: 2.293

5.  Dissection of hypothalamic-pituitary-adrenal axis pathology in 1-month-abstinent alcohol-dependent men, part 2: response to ovine corticotropin-releasing factor and naloxone.

Authors:  Bryon Adinoff; Steven R Krebaum; Patricia A Chandler; Wen Ye; Morton B Brown; Mark J Williams
Journal:  Alcohol Clin Exp Res       Date:  2005-04       Impact factor: 3.455

6.  Dissection of hypothalamic-pituitary-adrenal axis pathology in 1-month-abstinent alcohol-dependent men, part 1: adrenocortical and pituitary glucocorticoid responsiveness.

Authors:  Bryon Adinoff; Steven R Krebaum; Patricia A Chandler; Wen Ye; Morton B Brown; Mark J Williams
Journal:  Alcohol Clin Exp Res       Date:  2005-04       Impact factor: 3.455

Review 7.  The importance of glucocorticoids in alcohol dependence and neurotoxicity.

Authors:  A K Rose; S G Shaw; M A Prendergast; H J Little
Journal:  Alcohol Clin Exp Res       Date:  2010-09-07       Impact factor: 3.455

8.  Family history of alcoholism does not influence adrenocortical hyporesponsiveness in abstinent alcohol-dependent men.

Authors:  Elizabeth Hardin; Bryon Adinoff
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

9.  Naltrexone alters alcohol self-administration behaviors and hypothalamic-pituitary-adrenal axis activity in a sex-dependent manner in rats.

Authors:  Steven J Nieto; Cana B Quave; Therese A Kosten
Journal:  Pharmacol Biochem Behav       Date:  2018-02-24       Impact factor: 3.533

10.  Sex-specific dissociations in autonomic and HPA responses to stress and cues in alcohol-dependent patients with cocaine abuse.

Authors:  Helen C Fox; Kwang-Ik A Hong; Kristen M Siedlarz; Keri Bergquist; George Anderson; Mary Jeanne Kreek; Rajita Sinha
Journal:  Alcohol Alcohol       Date:  2009-09-30       Impact factor: 2.826

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.